Celldex Therapeutics Inc.

Clinical-stage biotech developing antibody therapeutics at the intersection of mast cell biology and inflammatory disease. Lead asset barzolvolimab, an anti-KIT mAb that depletes mast cells, is in Phase 3 for chronic spontaneous urticaria and chronic inducible urticaria, with Phase 2 readouts pending in atopic dermatitis and prurigo nodularis.